Enterprise Overview
Founded in 2011 and headquartered in Suzhou Industrial Park, Jiangsu Province, Innovent Biologics is a globally recognized biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapies. Focused on oncology, metabolic disorders, autoimmune diseases, and ophthalmology, it has built a robust R&D pipeline encompassing PD-1 inhibitors, bispecific antibodies, and ADCs (Antibody-Drug Conjugates). Its flagship product, Tyvyt® (sintilimab), a PD-1 inhibitor, has been approved for multiple indications in China and is undergoing international clinical trials. Innovent operates state-of-the-art manufacturing facilities compliant with GMP standards of NMPA, FDA, and EMA, ensuring high-quality drug production.
Business Scope
Innovent’s core offerings include:
· Oncology therapies: Tyvyt® (sintilimab) for multiple cancers, IBI363 (a PD-1/IL-2α-bias bispecific antibody), and IBI3009 (a DLL3-targeted ADC developed in collaboration with Roche).
· Metabolic and autoimmune diseases: Pipeline drugs such as GLP-1/GIP dual agonists.
· Global partnerships: Strategic collaborations with Eli Lilly (e.g., co-developing Tyvyt®) and Roche (ADC development), including a $108 million upfront payment for the global rights to IBI3009.
· Clinical development: Over 60 clinical trials across Asia, Australia, and the U.S., with a focus on registrational studies for global markets.
International Status
As a pioneer in China’s biotech sector, Innovent has achieved significant global milestones:
· PD-1 globalization: Tyvyt®’s overseas development through partnerships with Eli Lilly marks the first time a Chinese-developed PD-1 inhibitor entered global markets.
· ADC leadership: The collaboration with Roche on IBI3009 highlights its cutting-edge ADC technology, positioning Innovent as a key player in oncology innovation.
· Manufacturing excellence: Facilities audited by international regulatory bodies enable export capabilities and global supply chain integration.